vs
EXACT SCIENCES CORP（EXAS）与MongoDB, Inc.（MDB）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是MongoDB, Inc.的1.4倍（$878.4M vs $628.3M），MongoDB, Inc.净利率更高（-0.3% vs -9.8%，领先9.5%），EXACT SCIENCES CORP同比增速更快（23.1% vs 18.7%），MongoDB, Inc.自由现金流更多（$141.8M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 17.1%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
MongoDB Inc.是美国软件企业，核心业务为开发面向非结构化数据的数据库引擎MongoDB并提供相关商用技术支持。该产品脱胎于NoSQL数据库，后续新增ACID事务等能力，功能覆盖场景持续拓展，可充分满足全球企业级客户的多元需求。
EXAS vs MDB — 直观对比
营收规模更大
EXAS
是对方的1.4倍
$628.3M
营收增速更快
EXAS
高出4.4%
18.7%
净利率更高
MDB
高出9.5%
-9.8%
自由现金流更多
MDB
多$21.4M
$120.4M
两年增速更快
EXAS
近两年复合增速
17.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $628.3M |
| 净利润 | $-86.0M | $-2.0M |
| 毛利率 | 70.1% | 71.5% |
| 营业利润率 | -9.4% | -2.9% |
| 净利率 | -9.8% | -0.3% |
| 营收同比 | 23.1% | 18.7% |
| 净利润同比 | 90.1% | 79.5% |
| 每股收益（稀释后） | $-0.45 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASMDB
| Q4 25 | $878.4M | $628.3M | ||
| Q3 25 | $850.7M | $591.4M | ||
| Q2 25 | $811.1M | $549.0M | ||
| Q1 25 | $706.8M | $548.4M | ||
| Q4 24 | $713.4M | $529.4M | ||
| Q3 24 | $708.7M | $478.1M | ||
| Q2 24 | $699.3M | $450.6M | ||
| Q1 24 | $637.5M | $458.0M |
净利润EXASMDB
| Q4 25 | $-86.0M | $-2.0M | ||
| Q3 25 | $-19.6M | $-47.0M | ||
| Q2 25 | $-1.2M | $-37.6M | ||
| Q1 25 | $-101.2M | $15.8M | ||
| Q4 24 | $-864.6M | $-9.8M | ||
| Q3 24 | $-38.2M | $-54.5M | ||
| Q2 24 | $-15.8M | $-80.6M | ||
| Q1 24 | $-110.2M | $-55.5M |
毛利率EXASMDB
| Q4 25 | 70.1% | 71.5% | ||
| Q3 25 | 68.6% | 71.0% | ||
| Q2 25 | 69.3% | 71.2% | ||
| Q1 25 | 70.8% | 72.8% | ||
| Q4 24 | 69.0% | 74.4% | ||
| Q3 24 | 69.4% | 73.2% | ||
| Q2 24 | 69.8% | 72.8% | ||
| Q1 24 | 70.0% | 75.0% |
营业利润率EXASMDB
| Q4 25 | -9.4% | -2.9% | ||
| Q3 25 | -3.0% | -11.0% | ||
| Q2 25 | -0.3% | -9.8% | ||
| Q1 25 | -13.6% | -3.4% | ||
| Q4 24 | -122.8% | -5.3% | ||
| Q3 24 | -5.6% | -14.9% | ||
| Q2 24 | -3.8% | -21.8% | ||
| Q1 24 | -16.7% | -15.5% |
净利率EXASMDB
| Q4 25 | -9.8% | -0.3% | ||
| Q3 25 | -2.3% | -8.0% | ||
| Q2 25 | -0.1% | -6.9% | ||
| Q1 25 | -14.3% | 2.9% | ||
| Q4 24 | -121.2% | -1.8% | ||
| Q3 24 | -5.4% | -11.4% | ||
| Q2 24 | -2.3% | -17.9% | ||
| Q1 24 | -17.3% | -12.1% |
每股收益（稀释后）EXASMDB
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | $-0.54 | — | ||
| Q4 24 | $-4.69 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.60 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $834.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.9B |
| 总资产 | $5.9B | $3.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASMDB
| Q4 25 | $964.7M | $834.1M | ||
| Q3 25 | $1.0B | $647.1M | ||
| Q2 25 | $858.4M | $657.8M | ||
| Q1 25 | $786.2M | $490.1M | ||
| Q4 24 | $1.0B | $673.1M | ||
| Q3 24 | $1.0B | $1.3B | ||
| Q2 24 | $946.8M | $815.7M | ||
| Q1 24 | $652.1M | $803.0M |
股东权益EXASMDB
| Q4 25 | $2.4B | $2.9B | ||
| Q3 25 | $2.5B | $2.9B | ||
| Q2 25 | $2.5B | $3.0B | ||
| Q1 25 | $2.4B | $2.8B | ||
| Q4 24 | $2.4B | $1.5B | ||
| Q3 24 | $3.2B | $1.4B | ||
| Q2 24 | $3.2B | $1.3B | ||
| Q1 24 | $3.1B | $1.1B |
总资产EXASMDB
| Q4 25 | $5.9B | $3.6B | ||
| Q3 25 | $5.9B | $3.5B | ||
| Q2 25 | $5.8B | $3.6B | ||
| Q1 25 | $5.7B | $3.4B | ||
| Q4 24 | $5.9B | $3.2B | ||
| Q3 24 | $6.7B | $3.1B | ||
| Q2 24 | $6.7B | $3.0B | ||
| Q1 24 | $6.4B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $143.5M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $141.8M |
| 自由现金流率自由现金流/营收 | 13.7% | 22.6% |
| 资本支出强度资本支出/营收 | 3.6% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $346.3M |
8季度趋势，按日历期对齐
经营现金流EXASMDB
| Q4 25 | $151.7M | $143.5M | ||
| Q3 25 | $219.9M | $72.1M | ||
| Q2 25 | $89.0M | $109.9M | ||
| Q1 25 | $30.8M | $50.5M | ||
| Q4 24 | $47.1M | $37.4M | ||
| Q3 24 | $138.7M | $-1.4M | ||
| Q2 24 | $107.1M | $63.6M | ||
| Q1 24 | $-82.3M | $54.6M |
自由现金流EXASMDB
| Q4 25 | $120.4M | $141.8M | ||
| Q3 25 | $190.0M | $71.6M | ||
| Q2 25 | $46.7M | $108.3M | ||
| Q1 25 | $-365.0K | $24.6M | ||
| Q4 24 | $10.7M | $35.5M | ||
| Q3 24 | $112.6M | $-2.4M | ||
| Q2 24 | $71.2M | $63.1M | ||
| Q1 24 | $-120.0M | $51.9M |
自由现金流率EXASMDB
| Q4 25 | 13.7% | 22.6% | ||
| Q3 25 | 22.3% | 12.1% | ||
| Q2 25 | 5.8% | 19.7% | ||
| Q1 25 | -0.1% | 4.5% | ||
| Q4 24 | 1.5% | 6.7% | ||
| Q3 24 | 15.9% | -0.5% | ||
| Q2 24 | 10.2% | 14.0% | ||
| Q1 24 | -18.8% | 11.3% |
资本支出强度EXASMDB
| Q4 25 | 3.6% | 0.3% | ||
| Q3 25 | 3.5% | 0.1% | ||
| Q2 25 | 5.2% | 0.3% | ||
| Q1 25 | 4.4% | 4.7% | ||
| Q4 24 | 5.1% | 0.4% | ||
| Q3 24 | 3.7% | 0.2% | ||
| Q2 24 | 5.1% | 0.1% | ||
| Q1 24 | 5.9% | 0.6% |
现金转化率EXASMDB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.19× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
MDB
| Mongo DB Atlas Related | $470.4M | 75% |
| Other Subscription | $138.7M | 22% |
| Services | $19.2M | 3% |
